Roivant Sciences Ltd.
Health
Performance
3.5
Risk
Sell
Buy
Curious about the Scores? Learn more.

Roivant Sciences Ltd. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

07.02.2026
From average to promising. Starting to shine again.
07.02.2026
Calmer waters ahead. Risk signals cooling off.
12.10.2025
Outperforming hard. Momentum locked in.
ROIV
Roivant Sciences Ltd.
27.67
+7.16%
3.5
Sell
Buy
Roivant Sciences Ltd.

Roivant Sciences Ltd. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Roivant Sciences Ltd. do? Business model and key facts

Get the full picture of Roivant Sciences Ltd.: what it builds, where it operates, and how it makes money.

Roivant Sciences Ltd. Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): 908

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

shop
Company facts
Matthew Gline
CEO
908
Employees worldwide
shop
Performance
156.44%
Last 12 months
166.57%
Last 5 years
shop
Growth
$29,05M
Revenue year
$-356.734.000
Net income
shop
Valuation
$19,24B
Market Cap
-42.56
Price/Earnings Ratio

Stocks related to Roivant Sciences Ltd.

Selected based on industry alignment and relative market positioning.

UTHR
United Therapeutics Corporation
473.12
-2.52%
4.1
Sell
Buy
United Therapeutics Corporation
INCY
Incyte Corporation
109.03
+0.59%
3.7
Sell
Buy
Incyte Corporation
BNTX
BioNTech SE
110.34
+3.49%
6.9
Sell
Buy
BioNTech SE
RPRX
Royalty Pharma plc
44.05
-1.34%
2.4
Sell
Buy
Royalty Pharma plc
GMAB
Genmab A/S
30.87
-0.10%
4.4
Sell
Buy
Genmab A/S

Roivant Sciences Ltd. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.